Sleep Deprivation and Advancement of Sleep Period as Treatment for Bipolar Depression.
|Bipolar Disorder||Behavioral: Sleep deprivation and sleep phase advancement Other: usual treatment|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Sleep Deprivation and Three Days Sleep Phase Advancement as Treatment for Bipolar Depression.|
- Scores on rating scales for depression and symptom severity. [ Time Frame: one month ]
- Scores on rating scales for anxiety, mania, cognitive processing, and sleep quality. [ Time Frame: one month ]
|Study Start Date:||October 2005|
|Study Completion Date:||December 2011|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Experimental: Sleep deprivation
Sleep deprivation and sleep phase advancement
Behavioral: Sleep deprivation and sleep phase advancement
Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
|Active Comparator: usual treatment||
Other: usual treatment
Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
Background: The onset of therapeutic action for most anti-depressive treatments is usually two weeks. During this period patients suffer from great symptomatic distress. Treatment options that are effective in this period is therefore of interest for psychiatric wards.
Aim: To explore if sleep deprivation and three days sleep phase advancement is effective treatment for inpatients with bipolar disorder in a depressive phase.
Method: A randomized controlled trial with 24 patients diagnosed with bipolar disorder. Patients will be randomized to treatment as usual in an psychiatric ward, or sleep deprivation and three days sleep phase advancement. Patients in the treatment as usual group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00229151
|Norwegian University of Science and Technology, Institute of Neuroscience|
|Trondheim, Norway, 7489|
|Principal Investigator:||Gunnar Morken, PhD MD||Norwegian University of Science and Technology|